Tumor-to-liver ratio (TLR) by 68Ga-PSMA-11 PET/CT for response assessment and prediction of progressionfree survival in patients with mCRPC undergoing 177Lu-PSMA-617 radioligand therapy

被引：0
|
作者：
Khreish, F. [1 ]
Wiessner, M. [1 ]
Rosar, F. [1 ]
Ghazal, Z. [1 ]
Sabet, A. [2 ]
Maus, S. [1 ]
Linxweiler, J. [3 ]
Bartholomae, M. [1 ]
Ezziddin, S. [1 ]
机构：
[1] Saarland Univ, Dept Nucl Med, Homburg, Germany
[2] Frankfurt Univ, Dept Nucl Med, Frankfurt, Germany
[3] Saarland Univ, Dept Urol, Homburg, Germany
来源：
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING | 2021年 / 48卷 / SUPPL 1期
关键词：
D O I：
暂无
中图分类号：
R8 [特种医学]; R445 [影像诊断学];
学科分类号：
1002 ; 100207 ; 1009 ;
摘要：
OP-0900
引用
收藏
页码：S314 / S314
页数：1
相关论文
共 50 条
  • [1] Response Assessment and Prediction of Progression-Free Survival by 68Ga-PSMA-11 PET/CT Based on Tumor-to-Liver Ratio (TLR) in Patients with mCRPC Undergoing 177Lu-PSMA-617 Radioligand Therapy
    Khreish, Fadi
    Wiessner, Mona
    Rosar, Florian
    Ghazal, Zaidoon
    Sabet, Amir
    Maus, Stephan
    Linxweiler, Johannes
    Bartholomae, Mark
    Ezziddin, Samer
    BIOMOLECULES, 2021, 11 (08)
  • [2] 177Lu-PSMA-617 radioligand therapy of mCRPC: evaluation criteria of response
    Rahbar, Kambiz
    Boegemann, Martin
    Ahmadzadehfar, Hojjat
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2017, 44 (01) : 166 - 167
  • [3] 177Lu-PSMA-617 radioligand therapy of mCRPC: evaluation criteria of response
    Kambiz Rahbar
    Martin Bögemann
    Hojjat Ahmadzadehfar
    European Journal of Nuclear Medicine and Molecular Imaging, 2017, 44 : 166 - 167
  • [4] A VISION Substudy of Reader Agreement on 68Ga-PSMA-11 PET/CT Scan Interpretation to Determine Patient Eligibility for 177Lu-PSMA-617 Radioligand Therapy
    Kuo, Phillip H.
    Yoo, Don C.
    Avery, Ryan
    Seltzer, Marc
    Calais, Jeremie
    Nagarajah, James
    Weber, Wolfgang A.
    Fendler, Wolfgang P.
    Hofman, Michael S.
    Krause, Bernd J.
    Brackman, Marcia
    Kpamegan, Euloge
    Ghebremariam, Samson
    Benson, Taylor
    Catafau, Ana M.
    Kendi, Ayse T.
    JOURNAL OF NUCLEAR MEDICINE, 2023, 64 (08) : 1259 - 1265
  • [5] Initial Theranostics Experience Using 68Ga-PSMA-11 PET/CT and 177Lu-PSMA-617 in a Chilean Oncology Center
    Amaral, H.
    Fernandez, R.
    Kramer, V.
    Lavados, H.
    Hernandez, E.
    Morales, B.
    Pruzzo, R.
    Haeger, A.
    Ribbeck, J.
    Flores, J.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2017, 44 : S205 - S205
  • [6] 177Lu-PSMA-617 radioligand therapy of mCRPC: evaluation criteria of response Reply
    Yadav, Madhav Prasad
    Ballal, Sanjana
    Tripathi, Madhavi
    Bal, Chandrasekhal
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2017, 44 (01) : 168 - 169
  • [7] Can pre-therapy 68Ga-PSMA-11 PET SUVs predict absorbed doses across multiple cycles of 177Lu-PSMA-617 therapy of mCRPC patients?
    Brosch-Lenz, J.
    Colpo, N.
    Bloise, I.
    Hou, X.
    Parulekar, W. R.
    Dellar, C.
    Saad, F.
    Chi, K.
    Wilson, D.
    Benard, F.
    Rahmim, A.
    Uribe, C.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2023, 50 (SUPPL 1) : S324 - S324
  • [8] 68Ga-PSMA PET/CT for monitoring response to 177Lu-PSMA-617 radioligand therapy in patients with metastatic castration-resistant prostate cancer
    Heinzel, Alexander
    Boghos, Dima
    Mottaghy, Felix M.
    Gaertner, Florian
    Essler, Markus
    von Mallek, Dirk
    Ahmadzadehfar, Hojjat
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2019, 46 (05) : 1054 - 1062
  • [9] 44Sc-PSMA-617 for radiotheragnostics in tandem with 177Lu-PSMA-617—preclinical investigations in comparison with 68Ga-PSMA-11 and 68Ga-PSMA-617
    Christoph A. Umbricht
    Martina Benešová
    Raffaella M. Schmid
    Andreas Türler
    Roger Schibli
    Nicholas P. van der Meulen
    Cristina Müller
    EJNMMI Research, 7
  • [10] 68Ga-PSMA PET/CT for monitoring response to 177Lu-PSMA-617 radioligand therapy in patients with metastatic castration-resistant prostate cancer
    Alexander Heinzel
    Dima Boghos
    Felix M. Mottaghy
    Florian Gaertner
    Markus Essler
    Dirk von Mallek
    Hojjat Ahmadzadehfar
    European Journal of Nuclear Medicine and Molecular Imaging, 2019, 46 : 1054 - 1062
12345